Main image of with a Heart surrounded by an EMBLEM and a EMPOWER devices

EMBLEM™ MRI S-ICD Extrathoracic Protection, Low-Risk Profile

Proven Protection. Personalised Care.

The Only Device of its Kind

The EMBLEM™ Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System protects patients at risk of sudden cardiac death (SCD), while minimising complications linked to transvenous or substernal leads. Backed by decades of clinical evidence, the EMBLEM™ S-ICD offers extrathoracic protection with a low-risk profile.1–8 

Key Benefits

Icon: 150,000+ EMBLEM S-ICD implants worldwide

implants9

The legacy of EMBLEM™ S-ICD spans more than 20 years of clinical evidence, providing robust protection against SCD to over 150,000 patients worldwide.3,9,10 

Clinical Data
Icon: showing 92% fewer lead-related issues

lead-related complications6

The EMBLEM™ S-ICD reduces risks linked to transvenous or substernal leads by 92% compared with transvenous ICDs (TV-ICDs), offering a low-risk, long-term solution.6–8

Icon: first step in mCRM therapy journey

in an mCRM™ System11

The EMBLEM™ S-ICD integrates seamlessly with the EMPOWER™ Leadless Pacemaker (LP) to support a continuous, low-risk care pathway tailored to individual patient needs.2,6,7

Risk-Reducing Technology

Image of an EMBLEM S-ICD device

EMBLEM™ S-ICD: A Low-Risk Solution for SCD

Unlike traditional ICDs, EMBLEM™ S-ICD protects against SCD without the need for more invasive leads, reducing the risk of serious lead-related complications compared with TV-ICDs.

Discover how this extrathoracic system is redefining SCD prevention:

EMBLEM™ MRI S-ICD
Image of an EMPOWER device

mCRM™: Future-Ready Cardiac Care

EMBLEM S-ICD forms the foundation of a modular Cardiac Rhythm Management (mCRM™) System, offering a step-up solution for patients who may need antitachycardia pacing (ATP) in the future.

Explore the option to add the EMPOWER™ LP as needed:

mCRM™ System

References:

1.Bardy GH, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36–44.

2.Knops R, Olde Nordkamp L, Delnoy PP, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383(6):526–536.

3.Gold MR, Lambiase PD, El-Chami MF, et al. Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) Trial. Circulation. 2021;143(1):7–17.

4.Lambiase PD, Theuns DA, Murgatroyd F, et al. Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. Eur Heart J. 2022:43(21):2037–2050.

5.Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology/American Heart association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e190–e252.

6.Healey JS, Krahn AD, Bashir J, et al. Perioperative safety and early patient and device outcomes among subcutaneous versus transvenous implantable cardioverter defibrillator implantations: a randomized, multicenter trial. Ann Intern Med. 2022;175(12):165–1665.

7.Knops R, van der Stuijt W, Delnoy PP, et al. Efficacy and safety of appropriate shocks and antitachycardia pacing in transvenous and subcutaneous implantable defibrillators: an analysis of all appropriate therapy in the PRAETORIAN trial. Circulation. 2022;145(5):321–329.

8.Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.

9.Boston Scientific CRM Product Performance Report published December 4th, 2023 Data as of October 3rd, 2023.

10.Gold MR, Aasbo JD, Weiss R, et al. Infection in subcutaneous implantable cardioverter defibrillator patients: results from the S-ICD Post-approval study. Heart Rhythm. 2022;19(12):1993–2001.

11.Boston Scientific. Data on File.
 

ATP, antitachycardia pacing; ICD, implantable cardioverter defibrillator; LP, leadless pacemaker; mCRM, modular cardiac rhythm management; SCD, sudden cardiac death; S-ICD, subcutaneous ICD; TV-ICD, transvenous ICD.


CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.